Literature DB >> 25083237

Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?

Caroline Sirois1, Julie Couture2, Jean-Pierre Grégoire3.   

Abstract

Cardiovascular diseases (CVDs) represent a huge health burden for older patients with diabetes. Acetylsalicylic acid (ASA) has long been used as a cardioprotective agent in primary and secondary prevention of CVD. However, there are important issues regarding the benefits and risks of ASA therapy in primary prevention of CVDs, for the older group in general and for individuals of all ages with diabetes. In this review, we summarize the benefits and risks related to ASA therapy by outlining the evidence for older patients and for patients with diabetes. There appear to be significant gaps in knowledge. The balance of benefits and risks is not well defined but ASA treatment seems to be unfavorable in many older patients.

Entities:  

Keywords:  aspirin; cardiovascular diseases; diabetes; elderly; primary prevention

Year:  2012        PMID： 25083237      PMCID： PMC4110868          DOI： 10.1177/2042098612451267

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


  42 in total

1.  Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.

Authors:  Michael Pignone; Mark J Alberts; John A Colwell; Mary Cushman; Silvio E Inzucchi; Debabrata Mukherjee; Robert S Rosenson; Craig D Williams; Peter W Wilson; M Sue Kirkman
Journal:  Circulation       Date:  2010-05-27       Impact factor: 29.690

2.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

3.  The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines.

Authors:  Alan D Bell; André Roussin; Raymond Cartier; Wee Shian Chan; James D Douketis; Anil Gupta; Maria E Kraw; Thomas F Lindsay; Michael P Love; Neesh Pannu; Rémi Rabasa-Lhoret; Ashfaq Shuaib; Philip Teal; Pierre Théroux; Alexander G G Turpie; Robert C Welsh; Jean-François Tanguay
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

4.  Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70.

Authors:  Mark R Nelson; Danny Liew; Melanie Bertram; Theo Vos
Journal:  BMJ       Date:  2005-05-20

5.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.

Authors: 
Journal:  Lancet       Date:  1998-01-24       Impact factor: 79.321

Review 6.  Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.

Authors:  Michael Pignone; Craig D Williams
Journal:  Nat Rev Endocrinol       Date:  2010-09-21       Impact factor: 43.330

7.  Aspirin use and chronic diseases: a cohort study of the elderly.

Authors:  A Paganini-Hill; A Chao; R K Ross; B E Henderson
Journal:  BMJ       Date:  1989-11-18

8.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

9.  Randomised trial of prophylactic daily aspirin in British male doctors.

Authors:  R Peto; R Gray; R Collins; K Wheatley; C Hennekens; K Jamrozik; C Warlow; B Hafner; E Thompson; S Norton
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-30

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321
View more
  3 in total

1.  Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.

Authors:  Oleh Lushchak; Veronika Piskovatska; Olha Strilbytska; Iryna Kindrat; Nadya Stefanyshyn; Alexander Koliada; Volodymyr Bubalo; Kenneth B Storey; Alexander Vaiserman
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Systems pharmacology analysis of synergy of TCM: an example using saffron formula.

Authors:  Jianling Liu; Jingjing Liu; Fengxia Shen; Zonghui Qin; Meng Jiang; Jinglin Zhu; Zhenzhong Wang; Jun Zhou; Yingxue Fu; Xuetong Chen; Chao Huang; Wei Xiao; Chunli Zheng; Yonghua Wang
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

3.  A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk.

Authors:  Giuseppe Derosa; Amedeo Mugellini; Rosa M Pesce; Angela D'Angelo; Pamela Maffioli
Journal:  Cardiovasc Diabetol       Date:  2015-07-30       Impact factor: 9.951
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.